Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
zonnic mint munnholspúði 4 mg
niconovum ab - nicotinum - munnholspúði - 4 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
diltiazem hcl alvogen (dilmin) forðatafla 120 mg
alvogen ehf. - diltiazemum hýdróklóríð - forðatafla - 120 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
hydrokortison orion (hydrocortisone orion) tafla 10 mg
orion corporation - hydrocortisonum inn - tafla - 10 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
bufomix easyhaler innöndunarduft 160 míkróg/4,5 míkróg/skammt
orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 160 míkróg/4,5 míkróg/skammt
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
bufomix easyhaler innöndunarduft 320 míkróg/9 míkróg/skammt
orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320 míkróg/9 míkróg/skammt
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexamethasone hameln stungulyf, lausn 4 mg/ml
hameln pharma gmbh - dexamethasonum natríumfosfat - stungulyf, lausn - 4 mg/ml
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lyf til veikindi öndunarvegi sjúkdómum, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma in adults whose disease is not adequately controlled.